In the last decade, tremendous advances have completely revolutionized the treatment landscape of acute myeloid leukemia (AML). The application of sophisticated molecular biology tools has unveiled a plethora of genomic alterations, some of which have recently been recognized in pre-leukemic conditions (e.g. CHIP, CCUS, ARCH) with implications on AML ontogenesis.
The presence of peculiar aberrations has been linked to specific clinical outcomes, paving the way for targeted approaches leveraging these therapeutic vulnerabilities. The most recent diagnostic and prognostic schemes of AML have included these latest advances, further contributing to improving the clinical management of patients.
We welcome manuscripts addressing translational studies on acute myeloid leukemia, spanning from the characterization of specific genomic aberrations to the application of -omics to identify novel vulnerabilities and druggable targets. Especially important will be work addressing the molecular basis of AML pathogenesis, from initiation to mechanisms underpinning leukemia relapse. Given the recent release of 2022 AML diagnostic and prognostic schemes, we will also welcome any contribution aiming at their real-world application. In this molecular era, work directed towards the development and application of novel drugs targeting leukemia and/or its interaction with the microenvironment and the immune system is also invited.
Please note that the application of artificial intelligence to large -omics dataset and studies aiming at identifying novel AML subgroups with an impact on clinical outcome will be especially welcomed.
Original Research Articles on these topics are strongly encouraged, however, Reviews critically reporting the latest advances in the field will also be accepted for consideration.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
In the last decade, tremendous advances have completely revolutionized the treatment landscape of acute myeloid leukemia (AML). The application of sophisticated molecular biology tools has unveiled a plethora of genomic alterations, some of which have recently been recognized in pre-leukemic conditions (e.g. CHIP, CCUS, ARCH) with implications on AML ontogenesis.
The presence of peculiar aberrations has been linked to specific clinical outcomes, paving the way for targeted approaches leveraging these therapeutic vulnerabilities. The most recent diagnostic and prognostic schemes of AML have included these latest advances, further contributing to improving the clinical management of patients.
We welcome manuscripts addressing translational studies on acute myeloid leukemia, spanning from the characterization of specific genomic aberrations to the application of -omics to identify novel vulnerabilities and druggable targets. Especially important will be work addressing the molecular basis of AML pathogenesis, from initiation to mechanisms underpinning leukemia relapse. Given the recent release of 2022 AML diagnostic and prognostic schemes, we will also welcome any contribution aiming at their real-world application. In this molecular era, work directed towards the development and application of novel drugs targeting leukemia and/or its interaction with the microenvironment and the immune system is also invited.
Please note that the application of artificial intelligence to large -omics dataset and studies aiming at identifying novel AML subgroups with an impact on clinical outcome will be especially welcomed.
Original Research Articles on these topics are strongly encouraged, however, Reviews critically reporting the latest advances in the field will also be accepted for consideration.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
